Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.20 USD
Change Today +0.03 / 0.49%
Volume 180.9K
VBLT On Other Exchanges
As of 5:20 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

vascular biogenics ltd (VBLT) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/27/15 - $17.02
52 Week Low
03/13/15 - $3.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

vascular biogenics ltd (VBLT) Related Bloomberg News

View More Bloomberg News

vascular biogenics ltd (VBLT) Related Businessweek News

No Related Businessweek News Found

vascular biogenics ltd (VBLT) Details

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases in Israel. Its lead product candidates include VB-111, a gene-based biologic that has completed Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; in Phase II clinical trials to treat thyroid cancer; and in Phase I/II clinical trials for the treatment of ovarian cancer. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Or Yehuda, Israel.

33 Employees
Last Reported Date: 05/12/15
Founded in 2000

vascular biogenics ltd (VBLT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

vascular biogenics ltd (VBLT) Key Developments

VBL Therapeutics Reports Updated Interim Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma

VBL Therapeutics announced updated interim results from its ongoing Phase 2 study of VB-111 in patients with recurrent glioblastoma (rGBM). Data showed a statistically significant overall survival benefit in patients treated with VB-111 followed by VB-111 in ombination with bevacizumab (Avastin) upon disease progression, ompared to patients treated with VB-111 followed by bevacizumab alone (p=0.05). These study results will be presented in greater detail at VBL's Analyst and Investor Meeting, June 1, 2015, in conjunction with the 2015 American Society for Cancer Oncology (ASCO) Annual Meeting. These interim Phase 2 results include 46 patients with rGBM treated with VB-111; upon disease progression, 23 patients were treated with VB-111 in combination with bevacizumab, and 22 received bevacizumab alone. One patient remains stable on VB-111 alone at 18 months. VB-111 in combination with bevacizumab demonstrated significant improvement in overall survival, with median overall survival of 16 months, compared to eight months in patients on VB-111 followed by bevacizumab alone (p=0.05). VB-111 also demonstrated a statistically significant improvement over the historical bevacizumab data set from the BELOB trial, which looked at efficacy of bevacizumab, lomustine or a combination of both agents, and reported a median overall survival of eight months for bevacizumab in 50 patients with rGBM (p=0.003) 1. Consistent with its mode of action, which in rGBM may require more than several weeks to demonstrate clinical effects, VB-11 did not affect time to first progression. These data also suggest that VB-111 induces an immuno-therapeutic effect. Of the 46 patients who received VB-111, 25 patients spiked a fever post-dosing of VB-111 at least once, while 21 patients did not. Feverish patients demonstrated a median overall survival of 16 months, compared to non-feverish patients, who had a median overall survival of 8.5 months (p=0.03). This correlation between clinical efficacy and fever suggests that VB-111 can induce an immune response in patients and supports a role of the immune system as part of VB-111's mechanism of action. It also strengthens VB-111 preclinical findings, which showed an elevated immune response in tumors of VB-111-treated animals. The Phase 2 trial is a multi-center study designed to determine the safety, tolerability and efficacy of VB-111 in patients with rGBM. In the first stage of the study, patients were treated with VB-111 alone. Upon disease progression - defined according to the Response Assessment in Neuro-Oncology (RANO) criteria as a worsening of the patient's cancer with an increase of at least 25% in the overall mass of measurable tumors, the appearance of new tumors, the worsening of non-measurable tumors since the beginning of treatment, a need for increased dose of corticosteroids, or clinical deterioration - patients entered the second stage of the study, in which they received either bevacizumab alone as standard of care or bevacizumab in combination with VB-111. VBL's pivotal Phase 3 clinical trial will be led by Timothy Cloughesy, MD, Professor of Clinical Neurology and Director of the Neuro-Oncology Program, UCLA School of Medicine and is expected to initiate in mid-2015.

VBL Therapeutics to Present Phase 1/2a Data From VB-111 in Recurrent Platinum-Resistant Mullerian Cancer

VBL Therapeutics announced positive interim results from an investigator-initiated, Phase 1/2a trial of multiple dose VB-111 in recurrent platinum-resistant Müllerian (ovarian) cancer. The data demonstrated promising evidence of clinical benefit in patients with recurrent platinum-resistant Müllerian cancer who received VB-111 in conjunction with weekly paclitaxel. These Phase 1/2a data for VB-111 include 16 patients with platinum-resistant Müllerian cancer treated with multiple doses of VB-111 in combination with weekly paclitaxel. Tumor response data are available for 14 patients, four of whom received low dose of VB-111 (3x1012 VP-viral particles) together with paclitaxel at a lower (40mg) or full dose, as specified by the dose escalation protocol. Ten subjects received a full dose of both paclitaxel (80mg) and VB-111 (1013 VP). Six out of the ten subjects treated with the high dose (60%) met the GCIC criteria of at least 50% reduction in CA-125; none of the four subjects treated with low dose VB-111 showed reduction in CA-125. In this study, VB-111 was safe and well tolerated in combination with paclitaxel, with anticipated toxicities. The most frequent adverse events observed in the study were low-grade flu-like symptoms. This Phase 1/2a trial, run by Massachusetts General Hospital and Dana Farber Cancer Institute, was an open-label, dose-escalating study designed to determine the safety and tolerability of the combination of intravenous administration of VB-111 and paclitaxel in patients with platinum-resistant Müllerian cancer. VB-111 was administered as an intravenous infusion at escalating doses from 3x1012 to 1x1013 VPs, with repeat doses every two months in conjunction with weekly paclitaxel. 16 patients received up to six repeat doses of VB-111. Of these, 12 received a higher dose (1x1013) and four received a lower dose (3x1012).

Vascular Biogenics Ltd. Presents at UBS Global Healthcare Conference, May-18-2015

Vascular Biogenics Ltd. Presents at UBS Global Healthcare Conference, May-18-2015 . Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Dror Harats, Chief Executive Officer and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VBLT:US $6.20 USD +0.03

VBLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VBLT.
View Industry Companies

Industry Analysis


Industry Average

Valuation VBLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VASCULAR BIOGENICS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at